# Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

> **NCT03302234** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 568 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03302234
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-14
- **Primary completion:** 2020-09-01
- **Final completion:** 2022-09-07
- **Target enrollment:** 568 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03302234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03302234, "Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03302234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*